Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.63 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30689085 | 1.00 | ERN1 (0.63) | ERN1SIRT1CA1CA2CA4 | |
| SCHEMBL16431419 | 0.86 | ERN1 (0.57) | ERN1SIRT1CA1CA2CA4 | |
| SCHEMBL27865436 | 0.82 | ERN1 (0.57) | ERN1CA1CA2CA4CA6 | |
| SCHEMBL28753784 | 0.82 | ERN1 (0.57) | ERN1CA1CA2CA4CA6 | |
| SCHEMBL2921541 | 0.81 | ERN1 (0.52) | ERN1SIRT1 | |
| SCHEMBL9189245 | 0.77 | ERN1 (0.69) | ERN1 | |
| SCHEMBL29371317 | 0.77 | ERN1 (1.00) | ERN1CA1CA2 | |
| SCHEMBL2120180 | 0.77 | ERN1 (1.00) | ERN1CA1CA2 | |
| SCHEMBL5881501 | 0.77 | ERN1 (0.53) | ERN1SIRT1CA1CA2CA4 | |
| SCHEMBL10759987 | 0.76 | SIRT1 (0.46) | SIRT1CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117233299-A | Method for detecting halogenated polyphenol in drinking water by solid phase extraction-vacuum centrifugal concentration-liquid chromatography tandem mass spectrometry | 浙江大学 | 2023-12-15 | — | — | CN | claimed |
| WO-2024219864-A1 | NOVEL COMPOUND EXHIBITING SETDB1 INHIBITORY ACTIVITY, AND USE THEREOF | 주식회사 넷타겟 | 2024-10-24 | — | — | WO | disclosed |
| CN-117233299-A | Method for detecting halogenated polyphenol in drinking water by solid phase extraction-vacuum centrifugal concentration-liquid chromatography tandem mass spectrometry | 浙江大学 | 2023-12-15 | — | — | CN | disclosed |
| CN-117233299-A | Method for detecting halogenated polyphenol in drinking water by solid phase extraction-vacuum centrifugal concentration-liquid chromatography tandem mass spectrometry | 浙江大学 | 2023-12-15 | — | — | CN | disclosed |
| CN-108069929-B | 3-substituted coumarin derivative and application thereof, and GPR35 receptor agonist | 中国科学院大连化学物理研究所 | 2021-06-15 | — | — | CN | disclosed |
| US-20110119775-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | US | disclosed |
| US-7888332-B2 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-02-15 | — | — | US | disclosed |
| EP-1740532-A4 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | UNIV CALIFORNIA (US) | 2009-06-10 | — | — | EP | disclosed |
| US-20090048207-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-19 | — | — | US | disclosed |
| US-7414037-B2 | cystic fibrosis transmembrane conductance regulator protein inhibitor; 2-naphthalenylamino-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene][3-[4-(3-(PEG)n-thioureido)diphenyl)-thioureido]propanedioic acid dihydrazide (MalH-(PEG)nB); cystic fibrosis with forms of male infertility, secretory diarrhea | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1740532-A2 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | The Regents of the University of California (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050239740-A1 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-10-27 | — | — | US | disclosed |
| WO-2005094374-A2 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239740-A1 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | CFTR, ABCC5, SLC9A5 | ERN1 4230/4885SIRT1 1910/4885CA1 1969/4885 |
| US-20110119775-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, ABCC5, SLC9A5 | ERN1 4230/4885SIRT1 1910/4885CA1 1969/4885 |
| US-20090048207-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, ABCC5, SLC9A5 | ERN1 4230/4885SIRT1 1910/4885CA1 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.